An interventional study of Laparoscopic Sleeve Gastrectomy with Posterior Gastropexy and Standard Sleeve Gastrectomy in Obesity & Overweight, sponsored by Helwan University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Helwan University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Obesity with a site in Egypt — 32 open to participants now, 39 under way, none of them phase 3. Obesity · Egypt.
Among the 138 studies in Obesity with a site in Egypt, this one is the 70th largest by enrollment of the 102 interventional ones that give a count, is one of 26 that started in 2023, is one of 90 with no phase, and was the 135th registered.
11,560 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →32 of the 138 studies in Obesity with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 18+
Cairo University · Sites in Egypt
Ages 60–70 · Women only
Badr University · Sites in Egypt
Ages 36–58
Cairo University · Sites in Egypt
Ages 40–55
Cairo University · Sites in Egypt
Ages 18–60
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 2 · Phase 4 3
First in 2006; this study’s year is marked. 26 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 60 across the 102 interventional studies, 100 across the 36 observational. Of the 87 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 138 have an industry lead sponsor. The 10 most frequent:
Helwan University is the lead sponsor of 70 studies on the registry; 15 are open to participants now.
Helwan University has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
7 of the studies in Obesity with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07397572Cairo UniversityIron Supplementation and Anemia After Sleeve Gastrectomy | 2026-11 |
| NCT06901440Assiut UniversityBariatric Surgery for Obesity | 2026-12 |
| NCT07336797Abdelrahman MahmoudEffect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy | 2026-12-30 |
| NCT07683286Cairo UniversityPilates Exercises Versus Intermittent Fasting Diet on Physical and Metabolic Aging Process in Obese Perimenopausal Women | 2027-01-01 |
| NCT07857395Zagazig UniversityModified El-Ganzouri Risk Index for Predicting Difficult Intubation in Obese Patients | 2027-03-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 138 studies in Obesity with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial evaluates the clinical outcomes and quality of life in patients undergoing laparoscopic sleeve gastrectomy with or without posterior gastropexy. The primary objective is to assess the effectiveness of posterior gastropexy in reducing postoperative reflux and improving overall patient satisfaction, with a 12-month follow-up period.
This study is designed as a pilot randomized controlled trial to investigate the role and clinical impact of adding posterior gastropexy to laparoscopic sleeve gastrectomy. Gastroesophageal reflux disease (GERD) is a frequent postoperative concern following sleeve gastrectomy; therefore, this trial aims to evaluate whether a posterior gastropexy technique can effectively mitigate postoperative reflux symptoms and enhance the patient's overall quality of life.
Eligible patients undergoing sleeve gastrectomy are randomly allocated into two groups: the study group receiving sleeve gastrectomy combined with posterior gastropexy, and the control group undergoing standard sleeve gastrectomy alone. Perioperative outcomes, intraoperative details, and postoperative complications are systematically documented. Patients are monitored through scheduled postoperative visits and standardized scoring questionnaires, including quality-of-life assessments (such as the GIQLI score), over a comprehensive 12-month follow-up period to assess both short- and medium-term clinical benefits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo laparoscopic sleeve gastrectomy combined with posterior gastropexy technique.
Procedure: Laparoscopic Sleeve Gastrectomy with Posterior Gastropexy
Patients undergo standard laparoscopic sleeve gastrectomy alone without posterior gastropexy.
Procedure: Standard Sleeve Gastrectomy
Laparoscopic sleeve gastrectomy combined with posterior gastropexy to assess clinical outcomes and GERD reduction.
Standard laparoscopic sleeve gastrectomy procedure without posterior gastropexy.
Gastrointestinal Quality of Life
Assessment of the GIQLI total score based on 36 items covering physical, emotional, and social functioning, along with gastrointestinal symptoms, scored from 0 to 144.
Time frame: At 6 months and 1 year postoperatively
Body Mass Index
Measurement of the patient body mass index expressed in kilograms per meter squared (kg/m²).
Time frame: At 6 months and 1 year postoperatively
Plan to share: Yes — Yes, anonymized individual participant data will be made available upon reasonable request to the corresponding author.
No publications or documents are linked to this record.
Ran from Mar 2023 to primary completion in Apr 2025, 25 months.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 25 months is close to that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helwan University